One area that has attracted academic discussion, press coverage, and significant biotechnology/pharma R&D investment is concern about undesirable, collateral skeletal muscle mass (SMM) loss, and presumably by extension, loss of strength and function in people taking GLP-1 medications
1 in 8 adults taking a GLP-1 drug for weight loss, KFF reports About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds
This concentrated side effect burden can feel more challenging than the gradual, manageable nausea associated with weekly lower doses, even though total cumulative medication is equivalent
Acting so, at micromolar concentrations, physiological ascorbate, a fully reduced form of vitamin C (VC), can reduce harmful ROS